Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | GPR6 | P46095 | 2/20 | 0.35 |
| ▸ | IL1B | P01584 | 4/20 | 0.35 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
| ▸ | CCNC | P24863 | 2/20 | 0.31 |
| ▸ | CDK8 | P49336 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | F9 | P00740 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2933462 | 0.89 | GSK3B (0.41) | GSK3BIL1BBTKNLRP3CNR1 | |
| SCHEMBL13658210 | 0.85 | GSK3B (0.39) | GSK3BIL1BNLRP3ALDH1A1 | |
| SCHEMBL2930956 | 0.83 | GSK3B (0.43) | GSK3BIL1BNLRP3CNR1DPP4 | |
| SCHEMBL8037163 | 0.81 | GSK3B (0.47) | GSK3BGPR6IL1BPROKR1BTK | |
| SCHEMBL7956666 | 0.80 | GSK3B (0.47) | GSK3BGPR6IL1BBTKHCRTR1 | |
| Hydrochloric Acid SCHEMBL4281336 | 0.80 | GSK3B (0.46) | GSK3BGPR6IL1BPROKR1BTK | |
| Hydrochloric Acid SCHEMBL2247528 | 0.80 | GSK3B (0.46) | GSK3BGPR6IL1BBTKHCRTR1 | |
| SCHEMBL1919457 | 0.79 | GSK3B (0.45) | GSK3BGPR6IL1BNLRP3CNR1 | |
| SCHEMBL2935250 | 0.78 | JAK3 (0.42) | GSK3BGPR6DPP4 | |
| SCHEMBL1919395 | 0.78 | GSK3B (0.48) | GSK3BGPR6IL1BBTKNLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2229392-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE AS GSK3BETA INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-09-22 | — | — | EP | disclosed |
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2009-10-15 | — | — | US | disclosed |
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2009-10-15 | — | — | US | disclosed |
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2009-10-15 | — | — | US | disclosed |
| WO-2009074259-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009074259-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | THPO, IL5, TPMT | GSK3B 2707/4885GPR6 4622/4885IL1B 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.